ClinicalTrials.gg
Active, not recruitingNCT06079359MULBERRYUpdated May 28, 2026

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

A Phase 3 interventional study of ALXN1850 and Placebo in Hypophosphatasia, sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 32 sites in 16 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Hypophosphatasia by AstraZeneca — 4 open to participants now, 7 under way, 3 of them phase 3. Hypophosphatasia · AstraZeneca.

Enrollment
4th of 16
30 · median 13
Started
2024
with 2 others
Phase 3
3 of 25
none open now
Registered
21st of 25
by date

Among the 25 studies in Hypophosphatasia by AstraZeneca, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 3, and was the 21st registered.

Hypophosphatasia

46 studies on the registry are indexed under Hypophosphatasia; 11 are open to participants now.

Browse Hypophosphatasia studies →

Open to participants now

4 of the 25 studies in Hypophosphatasia by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 9 Hypophosphatasia studies recruiting now, 8 set no upper age limit and 1 stops at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hypophosphatasia by AstraZeneca, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.

03

Conditions studied

  • Hypophosphatasia

Browse trials for

Keywords

  • Hypophosphatasia
  • HPP
  • ALXN1850
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of HPP documented in the medical records, and the following criteria fulfilled without other probable cause than HPP:

    1. Presence of HPP-related rickets on skeletal X-rays during the Screening Period, with a minimum Rickets Severity Score (RSS) of 1.0 AND
    2. Serum ALP activity below the age- and sex-adjusted normal range during the Screening Period as measured by the Central Laboratory OR 2 documented serum ALP activity results, at least 15 days apart, below the age- and sex-adjusted local laboratory normal range during the 24 months before the Day 1 Visit. Note: Local laboratories need to be Clinical Laboratory Improvement Amendments (CLIA) or ISO 15189 certified, or have other local equivalent laboratory certification with Alexion's approval.
  • Must meet 1 of the following criteria:

    1. Documented ALPL gene variant (pathogenic, likely pathogenic, or variant of unknown significance) from a CLIA certified laboratory (Section 8.7)
    2. Plasma PLP above the (ULN) during the Screening Period (central or local laboratory results allowed per local regulations)
  • Tanner stage 2 or less during the Screening Period

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological disorders, or any other disorders that are capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data as determined by the Investigator
  • Diagnosis of primary or secondary hyperparathyroidism
  • Hypoparathyroidism, unless secondary to HPP
  • Any new fracture within 12 weeks before Day 1 (excluding pseudofractures)
  • Planned surgical intervention which may impact the results of study assessments (in the opinion of the Investigator) during the Randomized Evaluation Period
  • History of allergy or to any ingredient contained in ALXN1850 or the placebo comparator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    ALXN1850

    Starting at Day 1 of the Randomized Evaluation Period, the ALXN1850 group will receive bodyweight dependent doses of either 20mg, 35mg or 50mg of ALXN1850 once every 2 weeks (q2w) via SC injection, for 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.

    Drug: ALXN1850 · Drug: Placebo

  • Placebo comparator
    Placebo

    Starting at Day 1 during the Randomized Evaluation Period, participants will receive placebo q2w for a total of 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.

    Drug: Placebo

Interventions

  • Participants will receive a ALXN1850 via subcutaneous (SC) injection.

  • DrugPlacebo

    Participants will receive placebo via SC injection.

06

What researchers measure

Primary outcomes

  1. Radiographic Global Impression of Change (RGI-C) Score at the end of the Randomized Evaluation Period (Day 169)

    Time frame: Day 169

Secondary outcomes

  1. Change from Baseline in Rickets Severity Score (RSS) at the end of the Randomized Evaluation Period (Day 169)

    Time frame: Baseline, Day 169

  2. Change from Baseline in 6-Minute Walk Test (6MWT) at the end of the Randomized Evaluation Period (Day 169)

    Time frame: Baseline, Day 169

  3. Change from Baseline in Percent Predicted 6MWT at the end of the Randomized Evaluation Period (Day 169)

    Time frame: Baseline, Day 169

  4. Change from Baseline in Bruininks Oseretsky Test of Motor Proficiency, Second Edition (BOT2) Score at the end of the Randomized Evaluation Period (Day 169)

    Time frame: Baseline, Day 169

  5. Change from Baseline in Peabody Developmental Motor Scales, Third Edition (PDMS-3) Score at the end of the Randomized Evaluation Period (Day 169)

    Time frame: Baseline, Day 169

  6. RGI-C Responder at the end of the Randomized Evaluation Period (Day 169)

    Time frame: Day 169

07

Study locations

32 sites
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Kansas City, Missouri 64108, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Parkville, 3052, Australia
  • Research Site
    Brussels, 1020, Belgium
  • Research Site
    Brasília, 71625-009, Brazil
  • Research Site
    Porto Alegre, 90610-261, Brazil
  • Research Site
    Recife, 50740-465, Brazil
  • Research Site
    Salvador, 40050-410, Brazil
  • Research Site
    São Paulo, 01409-902, Brazil
  • Research Site
    São Paulo, 05403-900, Brazil
  • Research Site
    Calgary, Alberta T2E 7H7, Canada
  • Research Site
    Winnepeg, Manitoba R3E 3P4, Canada
  • Research Site
    Beijing, 100045, China
  • Research Site
    Guangzhou, 510623, China
  • Research Site
    Shanghai, 2000127, China
  • Research Site
    Shenzhen, 518053, China
  • Research Site
    Helsinki, 00290, Finland
  • Research Site
    Ashkelon, 7830604, Israel
  • Research Site
    Chihuahua City, 31238, Mexico
  • Research Site
    Lodz, 93-338, Poland
  • Research Site
    Bucharest, 011863, Romania
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Vitoria-Gasteiz, 01009, Spain
  • Research Site
    Stockholm, 17176, Sweden
  • Research Site
    Taipei, 100, Taiwan
  • Research Site
    Ankara, 06560, Turkey (Türkiye)
  • Research Site
    Bursa, 16059, Turkey (Türkiye)
  • Research Site
    Erzurum, 25240, Turkey (Türkiye)
  • Research Site
    Istanbul, 34899, Turkey (Türkiye)
  • Research Site
    Birmingham, B4 6NH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jan 2026, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2023
First posted
Oct 12, 2023
StartActual
May 14, 2024
Primary completionActual
Jan 6, 2026
CompletionEst.
Aug 24, 2028
Results delay requested
Mar 23, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06079359
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
May 14, 2024
Primary completion
Jan 6, 2026
Completion
Aug 24, 2028 (estimated)
Last update
May 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efzimfotase alfa

Start the discussion